<DOC>
	<DOCNO>NCT01284231</DOCNO>
	<brief_summary>To determine maximum tolerate dose and/or optimum biologic dose MEDI-565 adult subject evaluate safety profile adult subject advance gastrointestinal adenocarcinoma available standard curative treatment .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability MEDI-565 Adults With Gastrointestinal Adenocarcinomas</brief_title>
	<detailed_description>This FTIH , dose-escalation expansion Phase 1 study . The first part multicenter , open-label , single-arm , dose-escalation study MEDI-565 determine MTD OBD evaluate safety , tolerability , PK , IM , antitumor activity MEDI 565 adult subject GI adenocarcinomas standard curative treatment available . The second part dose-expansion study MTD OBD subject select tumor type .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Age ≥ 18 year age time screen Adequate contraception screen end trial For doseescalation phase , subject GI adenocarcinoma available standard curative treatment Adequate hematological function Adequate organ function For subject prior treatment chemotherapy , biological therapy , radiotherapy , prior surgery : eligible study entry least 30 day pass since treatment/surgery Life expectancy least 3 month Karnofsky performance status ≥ 70 % Body weight ≥ 45 kg Concurrent enrollment another clinical study Employees clinical study site individual involve conduct study , immediate family member individual Prior treatment MEDI565 History allergy reaction component MEDI565 formulation History malignancy GI adenocarcinoma , within 5 year prior study entry , exception ductal carcinoma situ breast , basal cell carcinoma skin carcinoma situ cervix successfully treat curative therapy Diagnosis hepatocellular carcinoma Clinical history significant CNS pathology Active bacterial infection know bacteremia . Vaccination within 2 week prior initiation MEDI565 Infection HIV1 HIV2 ; chronic infection hepatitis B C History primary immunodeficiency History chronic autoimmune disease Elective surgery plan study period 30 day discontinuation MEDI565 . Treatment chemotherapy , radiotherapy , immunotherapy , biologic , hormonal therapy cancer treatment within 30 day prior study entry recover treatment Treatment investigational agent within 30 day prior initiation MEDI565 Regular dose systemic corticosteroid 30 day prior initiation MEDI565 anticipate need corticosteroid exceed prednisone 40 mg/day prednisone equivalent trial , systemic immunosuppressive therapy within 30 day prior study entry ( maintenance dos allow ) Contraindication protocolspecified concomitant medication administer study Pregnancy lactation Evidence uncontrolled systemic disease ( GI adenocarcinoma ) Recent history cardiac disease , include myocardial infarction , unstable angina pectoris uncontrolled arrhythmia within 6 month , evidence severe congestive heart failure A mark baseline prolongation correct QT interval interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>MEDI-565 , gastrointestinal adenocarcinoma , carcinoembryonic antigen , bispecific T-cell engager</keyword>
</DOC>